Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 29 days to \< 6 years old. If the subject is born prematurely, calculation of the lower age limit begins at the corrected gestational age of 40 weeks.~* Signed informed consent by the subject's legally acceptable representative~* Suspected or confirmed UCD diagnosis of any subtype, except NAGS deficiency~* On stable dose of NaPBA powder for at least 5 days before Day 1~* Not receiving sodium benzoate for at least 5 days before Day 1~* No concomitant illness which would preclude safe participation as judged by the investigator~* Able to receive medication orally~* Has not undergone liver transplantation, including hepatocellular transplantation~* Judged sufficiently stable and compliant with diet and treatment to be suitable for enrollment~Exclusion Criteria:~* Screening ammonia level \> 100 μmol/L and signs and symptoms indicative of hyperammonemia; subjects may be rescreened after their ammonia is controlled and they are clinically stable, at the discretion of the investigator~* Use of any investigational drug within 30 days of Day 1~* Active infection (viral or bacterial) or any other condition that may increase ammonia levels~* Any clinical or laboratory abnormality of Grade 3 or greater severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03, except Grade 3 elevations in ammonia and liver enzymes, defined as levels 5-20 times ULN (upper limit of normal)in alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyl transpeptidase (GGT) in a clinically stable subject~* Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk by participating in this study~* Known hypersensitivity to PAA or PBA~* Liver transplant, including hepatocellular transplant~* Currently treated with Carbaglu® (carglumic acid)

- Gender: ALL
- Minimum Age: 29 Days
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- HPN-100 (Type: EXPERIMENTAL): Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).